JP7674628B2 - インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 - Google Patents

インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 Download PDF

Info

Publication number
JP7674628B2
JP7674628B2 JP2018543599A JP2018543599A JP7674628B2 JP 7674628 B2 JP7674628 B2 JP 7674628B2 JP 2018543599 A JP2018543599 A JP 2018543599A JP 2018543599 A JP2018543599 A JP 2018543599A JP 7674628 B2 JP7674628 B2 JP 7674628B2
Authority
JP
Japan
Prior art keywords
treatment
hdv
interferon lambda
patient
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505553A5 (https=
JP2019505553A (ja
Inventor
エドゥアルド・ブルーノ・マーティンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIT Pharma Inc
Original Assignee
EIT Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EIT Pharma Inc filed Critical EIT Pharma Inc
Publication of JP2019505553A publication Critical patent/JP2019505553A/ja
Publication of JP2019505553A5 publication Critical patent/JP2019505553A5/ja
Priority to JP2022140259A priority Critical patent/JP2022172279A/ja
Priority to JP2024125792A priority patent/JP2024156840A/ja
Application granted granted Critical
Publication of JP7674628B2 publication Critical patent/JP7674628B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018543599A 2016-02-19 2017-02-17 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 Active JP7674628B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022140259A JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297759P 2016-02-19 2016-02-19
US62/297,759 2016-02-19
PCT/US2017/018466 WO2017143253A1 (en) 2016-02-19 2017-02-17 Treatment of hepatitis delta virus infection with interferon lambda

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022140259A Division JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Publications (3)

Publication Number Publication Date
JP2019505553A JP2019505553A (ja) 2019-02-28
JP2019505553A5 JP2019505553A5 (https=) 2020-03-26
JP7674628B2 true JP7674628B2 (ja) 2025-05-12

Family

ID=59625481

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543599A Active JP7674628B2 (ja) 2016-02-19 2017-02-17 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2022140259A Pending JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A Pending JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022140259A Pending JP2022172279A (ja) 2016-02-19 2022-09-02 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
JP2024125792A Pending JP2024156840A (ja) 2016-02-19 2024-08-01 インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置

Country Status (17)

Country Link
US (2) US10953072B2 (https=)
EP (2) EP3416675B9 (https=)
JP (3) JP7674628B2 (https=)
KR (1) KR20180110127A (https=)
CN (1) CN108883156A (https=)
CY (1) CY1124220T1 (https=)
DK (1) DK3416675T3 (https=)
ES (2) ES2874592T3 (https=)
HR (1) HRP20210862T1 (https=)
HU (1) HUE055343T2 (https=)
LT (1) LT3416675T (https=)
PL (1) PL3416675T3 (https=)
PT (1) PT3416675T (https=)
RS (1) RS61944B1 (https=)
SI (1) SI3416675T1 (https=)
SM (1) SMT202100335T1 (https=)
WO (1) WO2017143253A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP7571008B2 (ja) * 2018-08-23 2024-10-22 アイガー・バイオファーマシューティカルズ・インコーポレイテッド インターフェロンラムダでのデルタ肝炎ウイルス感染処置
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
WO2021034101A1 (ko) * 2019-08-21 2021-02-25 한국과학기술원 신규 인터페론 람다 변이체 및 이의 제조방법
EP4045034A4 (en) * 2019-10-16 2023-05-24 Eiger Biopharmaceuticals, Inc. METHODS OF TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONS
EP4100047A4 (en) * 2020-02-06 2024-03-13 Eiger Biopharmaceuticals, Inc. TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135393D1 (de) 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
CA2520148A1 (en) 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
EP2251352A1 (en) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
WO2006076014A2 (en) 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
AU2006272937A1 (en) 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1912668A2 (en) 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
CA2625208A1 (en) 2005-10-04 2007-04-12 Zymogenetics, Inc. Production and purification of il-29
CN102886052B (zh) * 2006-09-14 2014-07-30 迈德詹尼克斯医疗以色列有限公司 长效药物制剂
KR101652767B1 (ko) 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
WO2011088126A2 (en) 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
CN103732250A (zh) * 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
US8454947B1 (en) 2012-03-01 2013-06-04 Nanogen Pharmaceutical Biotechnology PEG-interferon lambda 1 conjugates
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
PL3137078T3 (pl) * 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
EP3370723B1 (en) * 2015-11-04 2020-12-16 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
GB201621728D0 (en) 2016-12-20 2017-02-01 Ucb Biopharma Sprl Methods
JP7571008B2 (ja) 2018-08-23 2024-10-22 アイガー・バイオファーマシューティカルズ・インコーポレイテッド インターフェロンラムダでのデルタ肝炎ウイルス感染処置
US20220387432A1 (en) 2019-09-19 2022-12-08 Eip Pharma, Inc. Compositions and methods for treating prion disease
EP4100047A4 (en) 2020-02-06 2024-03-13 Eiger Biopharmaceuticals, Inc. TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531741A (ja) 2004-04-02 2007-11-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
JP2014525939A (ja) 2011-08-25 2014-10-02 ナノジェン・ファーマシューティカル・バイオテクノロジー ペグインターフェロンλ１複合体
JP2015528449A (ja) 2012-08-30 2015-09-28 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｇｉｅｒｓｃｈ、Ｋ．、ｅｔ ａｌ．、Ｐｅｇｙｌａｔｅｄ Ｉｎｔｅｒｆｅｒｏｎ Ｌａｍｂｄａ ｅｆｆｉｃｉｅｎｔｌｙ ｓｕｐｐｒｅｓｓｅｓ ＨＤＶ ｐｒｏｄｕｃｔｉｖｉｔｙ ａｎｄ ｓｈｏｗｓ ｃｏｍｐａｒａｂｌｅ ａｂｉｌｉｔｙ ｔｏ ｉｎｄｕｃｅ ＩＳＧｓ ａｓ ｐｅｇ－ＩＦＮα ｉｎ ＨＢＶ／ＨＤＶ ｃｏ－ｉｎｆｅｃｔｅｄ ｈｕｍａｎｉｚｅｄ ｍｉｃｅ、ＥＡＳＬ ＭｏｎｏｔｈｅｍａｔｉｃＣｏｎｆｅｒｅｎｃｅ ｏｎ Ｔｒａｎｓｌａｔｉｏｎａｌ Ｒｅｓｅａｒｃｈ ｉｎ Ｖｉｒａｌ Ｈｅｐａｔｉｔｉｓ ｉｎ Ｌｙｏｎ、Ｆｒａｎｃｅ、２０１３、＜ｈｔｔｐ：／／ｗｗｗ．ｅｉｇｅｒｂｉｏ．ｃｏｍ／ｒｅｓｏｕｒｃｅｓ／Ｇｉｅｒｓｃｈ－ＥＡＳＬ－２０１３．ｐｄｆ＞

Also Published As

Publication number Publication date
EP3416675B1 (en) 2021-03-24
KR20180110127A (ko) 2018-10-08
SMT202100335T1 (it) 2021-07-12
EP3416675A1 (en) 2018-12-26
US20210228686A1 (en) 2021-07-29
EP3416675A4 (en) 2020-01-08
HUE055343T2 (hu) 2022-05-28
US12508297B2 (en) 2025-12-30
HRP20210862T1 (hr) 2021-09-17
WO2017143253A1 (en) 2017-08-24
JP2022172279A (ja) 2022-11-15
JP2024156840A (ja) 2024-11-06
CN108883156A (zh) 2018-11-23
US10953072B2 (en) 2021-03-23
EP3957319A1 (en) 2022-02-23
PT3416675T (pt) 2021-06-14
RS61944B1 (sr) 2021-07-30
ES3008560T3 (en) 2025-03-24
EP3416675B9 (en) 2021-07-14
US20190111110A1 (en) 2019-04-18
SI3416675T1 (sl) 2021-09-30
ES2874592T3 (es) 2021-11-05
CY1124220T1 (el) 2022-05-27
DK3416675T3 (da) 2021-06-14
EP3957319B1 (en) 2024-12-04
JP2019505553A (ja) 2019-02-28
PL3416675T3 (pl) 2021-10-11
LT3416675T (lt) 2021-06-25

Similar Documents

Publication Publication Date Title
JP7674628B2 (ja) インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
Yuen et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection
JP7571008B2 (ja) インターフェロンラムダでのデルタ肝炎ウイルス感染処置
Antonelli et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-α2 therapy
DK2694087T3 (en) The treatment of infection with Hepatitis B virus alone or in combination with hepatitis delta virus, and in connection with liver diseases
JP2014532657A (ja) Ｃ型肝炎ウイルスを処置するための方法および組成物
EP4045034A1 (en) Methods to treat hepatitis delta viral infections
WO2024223797A1 (en) Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
EP4629969A1 (en) Methods to treat hepatitis delta viral infections
US20240108691A1 (en) Treatment of hepatitis e virus infection with interferon lambda
WO2021170741A1 (en) Treatment of hbv
WO2013137869A1 (en) Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250319

R150 Certificate of patent or registration of utility model

Ref document number: 7674628

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150